evolcSign inStart free
Menu

Amphista Therapeutics

Develops Targeted Glue protein-degrader medicines for cancer, with a lead acute myeloid leukemia candidate in Phase 1

Cambridge, United KingdomFounded 2017amphista.comWebsite technologies

+ Add to sales board

Highlights

  • New on EvolcAdded 2026-10-27

About Amphista Therapeutics

Amphista Therapeutics develops drugs based on targeted protein degradation. Its proprietary Targeted Glues use E3 ligases selected for each target protein, rather than relying only on CRBN-based approaches.

The lead programme, AMX-883, is a DCAF16-mediated BRD9 degrader for acute myeloid leukaemia. The FDA cleared its IND application in June 2026, and the first patient was dosed in a Phase 1 trial in October 2026. The pipeline also includes SMARCA2 and TEAD Targeted Glue programmes, for which preclinical data was presented at AACR 2026.

The company is based in Cambridge, United Kingdom, and was founded in 2017. It is supported by life science investors.

Product: AMX-883, a DCAF16-mediated BRD9 degrader for acute myeloid leukemia in Phase 1; SMARCA2 and TEAD degrader programmes in preclinical work.

Jobs at Amphista Therapeutics

No open positions listed right now.

More biotech & pharma companies

  • Ananda Pharma

    Develops cannabinoid-based medicines for inflammatory pain conditions and heart failure
    London, United KingdomBiotech & pharmaFounded 2018
    New on Evolc

  • Androlabs

    Men's health medicines, including testosterone replacement and erectile dysfunction therapies, for patients and healthcare professionals
    London, United KingdomBiotech & pharmaFounded 2021
    New on Evolc

  • Apis Assay Technologies

    Molecular diagnostic assay kits and contract IVD development for diagnostics, biotech and pharma teams
    Manchester, United KingdomBiotech & pharmaFounded 20181 open job
    New on Evolc

  • Apollo Therapeutics

    Portfolio biopharmaceutical company developing new medicines from university biomedical research and in-licensed clinical programs
    Cambridge, United KingdomBiotech & pharmaFounded 2021
    New on Evolc

  • Apterna

    Preclinical biotech developing liver-directed RNA therapies to restore liver function for patients with liver cancer
    London, United KingdomBiotech & pharmaFounded 2011
    New on Evolc

  • Arecor

    Develops therapeutics for people with diabetes, obesity and other cardiometabolic diseases
    Little Chesterford, United KingdomBiotech & pharmaFounded 2007
    New on Evolc

All biotech & pharma companies →

Website technologies

Older, unverified list. Detection dates and supporting evidence are not yet available.

  • Google Analytics 4
  • WordPress
  • jQuery
  • nginx